Ernexa Therapeutics Inc. (ERNA) · Nov 19, 2026 · Other events
$5,000 monthly CFO pay — $5,000 monthly cash compensation; ~$60,000 annualized
Ernexa’s latest 8-K adds $5,000 in monthly cash compensation to CFO Mark Keeley’s existing share-based consulting arrangement, without changing the company’s operating plan.
Ernexa is a preclinical synthetic allogeneic iMSC therapy company working to move its lead oncology program, ERNA-101, toward first-in-human development while building a broader cell-therapy pipeline.
The filing adds cash compensation, not operating progress. The board approved an addendum that supplements CFO Mark J. Keeley’s existing share-based compensation with $5,000 in monthly cash pay, effective November 9, 2026. 〔0〕 That is roughly $60,000 on an annualized basis—real incremental cash usage, but small relative to the company’s core clinical-development story.
The underlying CFO arrangement is otherwise unchanged. The addendum leaves the remaining consulting terms in place, so this does not represent a CFO transition, a change in strategy, or a new financing signal. 〔1〕
Bottom line: This is a routine compensation adjustment with a minor cash-burn implication, not a meaningful change to Ernexa’s preclinical-to-clinical story.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!